BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1136 related articles for article (PubMed ID: 33676449)

  • 1. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
    Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
    Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
    Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast-Conserving Therapy Versus Mastectomy in Young Breast Cancer Patients Concerning Molecular Subtypes: A SEER Population-Based Study.
    Yu P; Tang H; Zou Y; Liu P; Tian W; Zhang K; Xie X; Ye F
    Cancer Control; 2020; 27(1):1073274820976667. PubMed ID: 33356518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes.
    Chun YS; Mizuno T; Cloyd JM; Ha MJ; Omichi K; Tzeng CD; Aloia TA; Ueno NT; Kuerer HM; Barcenas CH; Vauthey JN
    Eur J Surg Oncol; 2020 Sep; 46(9):1588-1595. PubMed ID: 32253074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
    Press DJ; Miller ME; Liederbach E; Yao K; Huo D
    Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
    Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
    Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study.
    Kim EK; Noh WC; Han W; Noh DY
    World J Surg; 2011 Jun; 35(6):1244-53. PubMed ID: 21472372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population-based study.
    Xiao W; Zheng S; Liu P; Zou Y; Xie X; Yu P; Tang H; Xie X
    Cancer Med; 2018 Mar; 7(3):922-930. PubMed ID: 29473333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis.
    Gong Y; Zhang J; Ji P; Ling H; Hu X; Shao ZM
    Cancer Med; 2018 Aug; 7(8):4156-4169. PubMed ID: 29984914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.
    Caparica R; Richard F; Brandão M; Awada A; Sotiriou C; de Azambuja E
    Clin Breast Cancer; 2020 Jun; 20(3):262-273.e7. PubMed ID: 32229175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database.
    Hwang KT; Kim J; Jung J; Chang JH; Chai YJ; Oh SW; Oh S; Kim YA; Park SB; Hwang KR
    Clin Cancer Res; 2019 Mar; 25(6):1970-1979. PubMed ID: 30559169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
    Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
    J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.
    Ogiya R; Sagara Y; Niikura N; Freedman RA
    Clin Breast Cancer; 2019 Jun; 19(3):200-207.e1. PubMed ID: 30795886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
    Ge QD; Lv N; Kong YN; Xie XH; He N; Xie XM; Wei WD
    Asian Pac J Cancer Prev; 2012; 13(10):5081-6. PubMed ID: 23244114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.